Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 4 Researches
8.5
USERS' SCORE
Good
Based on 2 Reviews
8.4
Supplement Facts
Serving Size: 2 capsules
Amount Per Serving
%DV
Calories
5
Total Carbohydrates
<1 g
<1%
Sugars
<1 g
Protein
0.5 g
1%
Bovine Colostrum (Pasteurized Cow Pre-Milk)
945 mg
†
Immunoglobulins (IgG)
235 mg
†
Top Medical Research Studies
9
We analyzed how dupilumab, a treatment for severe asthma, affects a specific protein known as club cell secretory protein 16 (CC16) and other asthma-related symptoms. In our study, we included 25 patients who received dupilumab and underwent CT scans before and about four months after starting the treatment.
We found that treatment with dupilumab led to significant improvements in asthma symptoms, quality of life, and key lung function measures. The number of mucus plugs in patients' airways decreased, indicating better airway health. Interestingly, we observed that serum levels of CC16 increased significantly after treatment, suggesting that the protein plays a role in the airway's response to dupilumab.
Furthermore, changes in CC16 levels were positively linked with improvements in other important measures, such as exhaled nitric oxide and FEV1 (forced expiratory volume in one second). Overall, these findings imply that dupilumab may enhance respiratory function and alleviate asthma symptoms by positively altering the airway environment.
We found that treatment with dupilumab led to significant improvements in asthma symptoms, quality of life, and key lung function measures. The number of mucus plugs in patients' airways decreased, indicating better airway health. Interestingly, we observed that serum levels of CC16 increased significantly after treatment, suggesting that the protein plays a role in the airway's response to dupilumab.
Furthermore, changes in CC16 levels were positively linked with improvements in other important measures, such as exhaled nitric oxide and FEV1 (forced expiratory volume in one second). Overall, these findings imply that dupilumab may enhance respiratory function and alleviate asthma symptoms by positively altering the airway environment.
Read More
9
Bispecific antibody effectively treats asthma
We explored the therapeutic effects of a specially designed bispecific antibody, BiSpekDAb, on asthma, a condition often marked by swelling and tightness in the airways. This study utilized female Wistar rats and induced asthma using a mix of ovalbumin and lipopolysaccharide, setting the stage for us to see how effective BiSpekDAb could be over a series of subcutaneous injections.
Over the challenge phase, we noted significant declines in lung function and increases in both airway hyperresponsiveness and various immune cells like lymphocytes and eosinophils in the blood and lungs of the rats. The research also found elevated levels of inflammatory cytokines, signals that the body uses to manage inflammation, alongside visible histopathological changes—such as thickened airways and increased mucus production—characteristic of asthmatic conditions.
Importantly, when BiSpekDAb was administered, we saw a marked improvement in lung function and a decrease in inflammation related to asthma. The bispecific antibody effectively reduced levels of IL-23 and TNF-α, two inflammatory markers that contribute to asthma symptoms. Our findings suggest that targeting these pathways simultaneously could lead to more effective treatments for asthma, paving the way for new therapeutic possibilities.
Over the challenge phase, we noted significant declines in lung function and increases in both airway hyperresponsiveness and various immune cells like lymphocytes and eosinophils in the blood and lungs of the rats. The research also found elevated levels of inflammatory cytokines, signals that the body uses to manage inflammation, alongside visible histopathological changes—such as thickened airways and increased mucus production—characteristic of asthmatic conditions.
Importantly, when BiSpekDAb was administered, we saw a marked improvement in lung function and a decrease in inflammation related to asthma. The bispecific antibody effectively reduced levels of IL-23 and TNF-α, two inflammatory markers that contribute to asthma symptoms. Our findings suggest that targeting these pathways simultaneously could lead to more effective treatments for asthma, paving the way for new therapeutic possibilities.
Read More
8
We explored how specific proteins in sputum might help predict future asthma exacerbations. In our analysis of 22 sputum samples from patients in the AMAZES study, we identified over 500 proteins that differed significantly between those who did and did not experience exacerbations in the following 48 weeks. This discovery led us to develop a more focused model featuring 260 proteins, which showed promising predictive capabilities with a high accuracy rate.
Upon validating our findings with sputum samples from an additional 123 participants, we narrowed it down to nine key proteins linked to an increased risk of exacerbations. While we found that these proteins and the associated pathways—especially those related to inflammation and immune response—play a role in understanding asthma exacerbations, the study did not investigate the effects of stand-alone protein treatments on asthma patients directly. Therefore, we cannot conclude any potential benefits of direct protein therapies based solely on our findings.
Upon validating our findings with sputum samples from an additional 123 participants, we narrowed it down to nine key proteins linked to an increased risk of exacerbations. While we found that these proteins and the associated pathways—especially those related to inflammation and immune response—play a role in understanding asthma exacerbations, the study did not investigate the effects of stand-alone protein treatments on asthma patients directly. Therefore, we cannot conclude any potential benefits of direct protein therapies based solely on our findings.
Read More
Most Useful Reviews
9
Mild colds now
6 people found this helpful
This is a must-have. This product helps my family stay healthy during cold season. Last year my 5-year-old suffered from colds, ear infections, and asthma every eight days, necessitating weekly visits to the paediatrician. Since using this, if he catches a cold, it is milder. I also give him Mullein leaf tea.
Read More
7.5
Avoided illness
16 people found this helpful
I am a sceptic, but my daughter urged me to try these as I have severe to moderate asthma. I began taking these as I felt unwell, and remarkably, I improved before getting sick. For about 7 months, I have avoided illness. I take 2 capsules once a day, and if I feel that itchy feeling, I take 3 twice daily until it subsides, usually within two days. These seem to be keeping me away from the doctor and steroids, which is beneficial for my lungs.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 4 Researches
8.5
- All Researches
9
We analyzed how dupilumab, a treatment for severe asthma, affects a specific protein known as club cell secretory protein 16 (CC16) and other asthma-related symptoms. In our study, we included 25 patients who received dupilumab and underwent CT scans before and about four months after starting the treatment.
We found that treatment with dupilumab led to significant improvements in asthma symptoms, quality of life, and key lung function measures. The number of mucus plugs in patients' airways decreased, indicating better airway health. Interestingly, we observed that serum levels of CC16 increased significantly after treatment, suggesting that the protein plays a role in the airway's response to dupilumab.
Furthermore, changes in CC16 levels were positively linked with improvements in other important measures, such as exhaled nitric oxide and FEV1 (forced expiratory volume in one second). Overall, these findings imply that dupilumab may enhance respiratory function and alleviate asthma symptoms by positively altering the airway environment.
We found that treatment with dupilumab led to significant improvements in asthma symptoms, quality of life, and key lung function measures. The number of mucus plugs in patients' airways decreased, indicating better airway health. Interestingly, we observed that serum levels of CC16 increased significantly after treatment, suggesting that the protein plays a role in the airway's response to dupilumab.
Furthermore, changes in CC16 levels were positively linked with improvements in other important measures, such as exhaled nitric oxide and FEV1 (forced expiratory volume in one second). Overall, these findings imply that dupilumab may enhance respiratory function and alleviate asthma symptoms by positively altering the airway environment.
Read More
9
Bispecific antibody effectively treats asthma
We explored the therapeutic effects of a specially designed bispecific antibody, BiSpekDAb, on asthma, a condition often marked by swelling and tightness in the airways. This study utilized female Wistar rats and induced asthma using a mix of ovalbumin and lipopolysaccharide, setting the stage for us to see how effective BiSpekDAb could be over a series of subcutaneous injections.
Over the challenge phase, we noted significant declines in lung function and increases in both airway hyperresponsiveness and various immune cells like lymphocytes and eosinophils in the blood and lungs of the rats. The research also found elevated levels of inflammatory cytokines, signals that the body uses to manage inflammation, alongside visible histopathological changes—such as thickened airways and increased mucus production—characteristic of asthmatic conditions.
Importantly, when BiSpekDAb was administered, we saw a marked improvement in lung function and a decrease in inflammation related to asthma. The bispecific antibody effectively reduced levels of IL-23 and TNF-α, two inflammatory markers that contribute to asthma symptoms. Our findings suggest that targeting these pathways simultaneously could lead to more effective treatments for asthma, paving the way for new therapeutic possibilities.
Over the challenge phase, we noted significant declines in lung function and increases in both airway hyperresponsiveness and various immune cells like lymphocytes and eosinophils in the blood and lungs of the rats. The research also found elevated levels of inflammatory cytokines, signals that the body uses to manage inflammation, alongside visible histopathological changes—such as thickened airways and increased mucus production—characteristic of asthmatic conditions.
Importantly, when BiSpekDAb was administered, we saw a marked improvement in lung function and a decrease in inflammation related to asthma. The bispecific antibody effectively reduced levels of IL-23 and TNF-α, two inflammatory markers that contribute to asthma symptoms. Our findings suggest that targeting these pathways simultaneously could lead to more effective treatments for asthma, paving the way for new therapeutic possibilities.
Read More
8
We explored how specific proteins in sputum might help predict future asthma exacerbations. In our analysis of 22 sputum samples from patients in the AMAZES study, we identified over 500 proteins that differed significantly between those who did and did not experience exacerbations in the following 48 weeks. This discovery led us to develop a more focused model featuring 260 proteins, which showed promising predictive capabilities with a high accuracy rate.
Upon validating our findings with sputum samples from an additional 123 participants, we narrowed it down to nine key proteins linked to an increased risk of exacerbations. While we found that these proteins and the associated pathways—especially those related to inflammation and immune response—play a role in understanding asthma exacerbations, the study did not investigate the effects of stand-alone protein treatments on asthma patients directly. Therefore, we cannot conclude any potential benefits of direct protein therapies based solely on our findings.
Upon validating our findings with sputum samples from an additional 123 participants, we narrowed it down to nine key proteins linked to an increased risk of exacerbations. While we found that these proteins and the associated pathways—especially those related to inflammation and immune response—play a role in understanding asthma exacerbations, the study did not investigate the effects of stand-alone protein treatments on asthma patients directly. Therefore, we cannot conclude any potential benefits of direct protein therapies based solely on our findings.
Read More
8
This study aimed to compare the effectiveness of CT-P39, a new protein treatment delivered via an auto-injector, with omalizumab, a well-established treatment using a pre-filled syringe, in managing asthma symptoms. We conducted an open-label, Phase 1 study involving a total of 129 healthy Japanese adults, who were randomized to receive either CT-P39 or omalizumab.
We particularly looked at pharmacokinetic measures, which include how the medication is absorbed and processed in the body. Our main goal was to establish whether these two treatments produced similar results. We concluded that CT-P39 was indeed pharmacokinetically equivalent to omalizumab. This means that the way both treatments acted in the body was comparable.
Importantly, we did not find any serious adverse events related to either treatment, suggesting that both were safe. However, although the study shows that the two treatments exhibit comparable effectiveness in how they function within the body, it does not provide extensive details on how they may directly impact asthma symptoms or lead to clinical improvements.
Overall, while both treatments appear safe and equivalent in their pharmacokinetic profiles, the specific impact on asthma control was not fully addressed in this study.
We particularly looked at pharmacokinetic measures, which include how the medication is absorbed and processed in the body. Our main goal was to establish whether these two treatments produced similar results. We concluded that CT-P39 was indeed pharmacokinetically equivalent to omalizumab. This means that the way both treatments acted in the body was comparable.
Importantly, we did not find any serious adverse events related to either treatment, suggesting that both were safe. However, although the study shows that the two treatments exhibit comparable effectiveness in how they function within the body, it does not provide extensive details on how they may directly impact asthma symptoms or lead to clinical improvements.
Overall, while both treatments appear safe and equivalent in their pharmacokinetic profiles, the specific impact on asthma control was not fully addressed in this study.
Read More
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
9
Mild colds now
6 people found this helpful
This is a must-have. This product helps my family stay healthy during cold season. Last year my 5-year-old suffered from colds, ear infections, and asthma every eight days, necessitating weekly visits to the paediatrician. Since using this, if he catches a cold, it is milder. I also give him Mullein leaf tea.
Read More
7.5
Avoided illness
16 people found this helpful
I am a sceptic, but my daughter urged me to try these as I have severe to moderate asthma. I began taking these as I felt unwell, and remarkably, I improved before getting sick. For about 7 months, I have avoided illness. I take 2 capsules once a day, and if I feel that itchy feeling, I take 3 twice daily until it subsides, usually within two days. These seem to be keeping me away from the doctor and steroids, which is beneficial for my lungs.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Jurak LM, Yang IA, Simpson JL, Gibson PG, Hill MM, et al. Predicting future exacerbations in uncontrolled asthma: a discovery/validation approach using large-scale clinical proteomics. J Allergy Clin Immunol. 2025. doi:10.1016/j.jaci.2025.02.028
- Murai Y, Koya T, Koda H, Uji W, Tanaka M, et al. Dupilumab Efficacy in Relation to Changes in Club Cell Secretory Protein 16. Ann Allergy Asthma Immunol. 2025. doi:10.1016/j.anai.2025.02.019
- Hasunuma T, Grattan C, Eto T, Yagi M, Yazawa R, et al. Pharmacokinetics and safety of CT‑P39 via auto-injector are comparable to reference omalizumab via pre-filled syringe. Immunotherapy. 2025;17:113. doi:10.1080/1750743X.2025.2467026
- Gala CK, Pande AH, Sharma SS. Bispecific domain antibody attenuates airway hyperresponsiveness and pulmonary inflammation in ovalbumin-lipopolysaccharide induced asthma model by inhibiting IL-23 and TNF-α. Pulm Pharmacol Ther. 2025;88:102347. doi:10.1016/j.pupt.2025.102347
